Cancer Research Journal

| Peer-Reviewed |

Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting

Received: Aug. 16, 2023    Accepted: Sep. 01, 2023    Published: Sep. 14, 2023
Views:       Downloads:

Share

Abstract

Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor.

DOI 10.11648/j.crj.20231103.14
Published in Cancer Research Journal ( Volume 11, Issue 3, September 2023 )
Page(s) 105-111
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Ovarian Cancer, Treatment, Breast Cancer, Guinean Oncological Environment

References
[1] Institut Curie. Breast cancer. [Accessed March 11, 2021]. Available at: https://curie.fr/page/le-cancer-du-sein
[2] Lokossou A. Ovarian cancer: epidemiology, natural history, clinical study. Cours université d'Abomey- Calavi Bénin: 82p. [Accessed 04 February 2021]. Available from http://umvf.cerimes.fr/media/ressMereEnfant/CAN/Libreville2012/videocours/3-02-Libreville2012-Lokossou_html5/media/pdf/3.02_Lokossou.pdf
[3] Schonfeld SJ, Berrington de Gonzalez A, Visvanathan K, et al. Declining second primary ovarian cancer after first primary breast cancer. J Clin Oncol. 2013; 31 (6): 738-43.a.
[4] Zoukar O, Haddad A, Daldoul A et al. Genital metastases from breast cancer: study of 3 cases and literature review. Pan Afr Med J. 2018; 30 (7): 7.
[5] Curtis RE, Freedman DM, Ron E, et al. New malignancies among cancer survivors. [Accessed 06 February 2021]. Available at: https://seer.cancer.gov/archive/publications/mpmono/
[6] Crouet H, Lesur A, Blanc-Fournier C et al. Ovarian, peritoneal and retroperitoneal metastases in breast cancer. 29th meeting of the French Society of Senology and Breast Pathology (SFSPM). Advanced breast cancer. Avignon, France. 2007. 239p.
[7] Wang J., Tian W., Zhou Y. et al. Ovarian metastasis from breast cancer in three Chinese females: Three case reports. China: Wolters Kluwer Health, Inc; 2019; 98 (17); e15395.
[8] Dubois N., Willems T., Myant N. Métastase ovarienne du cancer du sein: à propos d'un cas. Rôle de la chirurgie cytoréductrice. Eur J Obst Gyn Reprod Biol; 2009; 38 (3): 242-245.
[9] Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin. 2009 59 (4): 225-49.
[10] Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011; 284 (5): 1283-8.
[11] Chabbert-Buffet N, Seroussi B, Chopier J et al. Modalités de fonctionnement d'un centre de prise en charge des femmes à haut risque de cancer du sein et de l'ovaire: l'expérience française de l'hôpital Tenon. Gynecol Obstet Fertil. 2010; 38 (3): 183-92.
[12] Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre-and perioperative characteristics. Gynecol Oncol. 2006; 101 (1): 97-101.
[13] Le Thai N, Lasry S, Brunet M et al. Cancer de l'ovaire après cancer du sein. 45 cars. J Gynecol Obstet Biol Reprod (Paris). 1991; 20 (8): 1043-8.
[14] Gagnon Y, Têtu B. Métastases ovariennes d'un carcinome mammaire. Etude clinicopathologique de 59 cas. Cancer. 1989; 64 (4): 892-8.
[15] Le Bouëdec G, de Latour M, Levrel O, Dauplat J. Tumeurs de krükenberg d'origine mammaire. 10 observations. Presse Med. 1997 Mar 29; 26 (10): 454-7.
[16] Perrotin F, Marret H, Bouquin R et al. Incidence, diagnostic et pronostic des métastases ovariennes dans le cancer du sein. Gynecol Obstet Fertil. 2001; 29 (4): 308-15.
[17] Société canadienne du cancer. Facteurs de risque du cancer du sein. [Consulté le 03 mai 2021]. Disponible sur: https://www.cancer.ca:443/fr-ca/cancer-information/cancertype/breast/risks/?region=qc.
[18] Rabban JT, Barnes M, Chen L-M et al. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009; 33 (8): 1125-36.
[19] Ayhan A, Guvenal T, Salman MC et al. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol. 2005; 98 (2): 235-41.
[20] Abu-Rustum NR, Aghajanian CA, Venkatraman ES et al. Metastatic breast carcinoma to the abdomen and pelvis. Gynecol Oncol. 1997; 66 (1): 41-4.
[21] Han X, Jemal A. Recent Patterns in Genetic Testing for Breast and Ovarian Cancer Risk in the U. S. Am J Prev Med. 2017; 53 (4): 504-7.
[22] Schneider J, Lahl J, Kramer W. Risque de cancer du sein à long terme après stimulation ovarienne chez les jeunes donneuses d'ovules: un appel au suivi, à la recherche et au consentement éclairé. Reprod Biomed Online. 2017; 34 (5): 480-5.
Cite This Article
  • APA Style

    Bah Malick, Toure Alhassane Ismael, Keita Mamady, Cisse Kalil, Souare Mamadou Bobo, et al. (2023). Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Research Journal, 11(3), 105-111. https://doi.org/10.11648/j.crj.20231103.14

    Copy | Download

    ACS Style

    Bah Malick; Toure Alhassane Ismael; Keita Mamady; Cisse Kalil; Souare Mamadou Bobo, et al. Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Res. J. 2023, 11(3), 105-111. doi: 10.11648/j.crj.20231103.14

    Copy | Download

    AMA Style

    Bah Malick, Toure Alhassane Ismael, Keita Mamady, Cisse Kalil, Souare Mamadou Bobo, et al. Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting. Cancer Res J. 2023;11(3):105-111. doi: 10.11648/j.crj.20231103.14

    Copy | Download

  • @article{10.11648/j.crj.20231103.14,
      author = {Bah Malick and Toure Alhassane Ismael and Keita Mamady and Cisse Kalil and Souare Mamadou Bobo and Conde Ibrahima Kalil and Cisse Mohamed Falilou and Traore Bangaly},
      title = {Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting},
      journal = {Cancer Research Journal},
      volume = {11},
      number = {3},
      pages = {105-111},
      doi = {10.11648/j.crj.20231103.14},
      url = {https://doi.org/10.11648/j.crj.20231103.14},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.crj.20231103.14},
      abstract = {Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor.},
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Ovarian Cancer After Breast Cancer Treatment: Study of 03 Cases in a Guinean Oncological Setting
    AU  - Bah Malick
    AU  - Toure Alhassane Ismael
    AU  - Keita Mamady
    AU  - Cisse Kalil
    AU  - Souare Mamadou Bobo
    AU  - Conde Ibrahima Kalil
    AU  - Cisse Mohamed Falilou
    AU  - Traore Bangaly
    Y1  - 2023/09/14
    PY  - 2023
    N1  - https://doi.org/10.11648/j.crj.20231103.14
    DO  - 10.11648/j.crj.20231103.14
    T2  - Cancer Research Journal
    JF  - Cancer Research Journal
    JO  - Cancer Research Journal
    SP  - 105
    EP  - 111
    PB  - Science Publishing Group
    SN  - 2330-8214
    UR  - https://doi.org/10.11648/j.crj.20231103.14
    AB  - Introduction: Ovarian cancer, the 1st cause of death from gynecological cancer, is any malignant proliferative process developed in the ovary, which may occur after a treated breast cancer. Objectives: To discuss the management and prognosis of ovarian cancer after breast cancer treatment through a series of 3 clinical cases in a Guinean oncology setting. Case 1: A 60-year-old patient presented with an ulcerating tumor of the uterine cervix, after treatment of a CCI, she benefited from 12 courses of palliative chemotherapy and died 04 months after her last course with decompensated anemia. Case 2: the 75-year-old female patient who presented with abdominal distension with ascites associated with a pelvic mass after treatment of a CCI, died of multivisceral failure. Case 3: A 61-year-old hypertensive diabetic patient presented with abdominal distension and a pelvic-abdominal mass. After treatment of a CCI, she underwent an exploratory laparotomy and died at D15 post-op in hypovolaemic shock. Conclusion: This study shows the need to include monitoring of gynecological organs in patients treated for breast cancer. The diagnosis was late and the prognosis was poor.
    VL  - 11
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Surgical Oncology Unit at Donka National Hospital, Conakry University Hospital, Conakry, Guinea

  • Section